Equities Analysts Offer Predictions for CAPR Q1 Earnings

Capricor Therapeutics Inc (NASDAQ:CAPR) – Stock analysts at HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for Capricor Therapeutics in a research note issued to investors on Thursday, March 20th. HC Wainwright analyst J. Pantginis anticipates that the biotechnology company will post earnings of ($0.35) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $77.00 price target on the stock. The consensus estimate for Capricor Therapeutics’ current full-year earnings is ($1.21) per share. HC Wainwright also issued estimates for Capricor Therapeutics’ Q3 2025 earnings at $0.94 EPS, Q4 2025 earnings at ($0.39) EPS, FY2025 earnings at $0.15 EPS and FY2026 earnings at ($0.61) EPS.

Separately, Cantor Fitzgerald restated an “overweight” rating and set a $30.00 target price on shares of Capricor Therapeutics in a research report on Thursday, March 20th. One research analyst has rated the stock with a sell rating and six have assigned a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $34.50.

Capricor Therapeutics Stock Up 3.3 %

Capricor Therapeutics stock opened at $13.28 on Monday. Capricor Therapeutics has a 52-week low of $3.52 and a 52-week high of $23.40. The company has a market cap of $603.84 million, a price-to-earnings ratio of -12.53 and a beta of 4.10. The firm’s fifty day moving average is $14.07 and its 200 day moving average is $14.76.

Capricor Therapeutics (NASDAQ:CAPR) last posted its earnings results on Wednesday, March 19th. The biotechnology company reported ($0.16) EPS for the quarter, beating analysts’ consensus estimates of ($0.31) by $0.15. Capricor Therapeutics had a negative return on equity of 112.95% and a negative net margin of 146.86%. The firm had revenue of $11.13 million during the quarter, compared to the consensus estimate of $9.87 million.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of CAPR. Farallon Capital Management LLC purchased a new position in shares of Capricor Therapeutics during the 4th quarter worth about $31,056,000. Vanguard Group Inc. boosted its position in shares of Capricor Therapeutics by 44.4% during the fourth quarter. Vanguard Group Inc. now owns 2,276,784 shares of the biotechnology company’s stock valued at $31,420,000 after buying an additional 700,243 shares during the period. Woodline Partners LP purchased a new position in shares of Capricor Therapeutics during the fourth quarter valued at approximately $8,693,000. Altium Capital Management LLC grew its stake in shares of Capricor Therapeutics by 150.5% during the fourth quarter. Altium Capital Management LLC now owns 714,000 shares of the biotechnology company’s stock valued at $9,853,000 after buying an additional 429,000 shares during the last quarter. Finally, Black Diamond Financial LLC purchased a new stake in shares of Capricor Therapeutics in the fourth quarter worth approximately $3,833,000. Institutional investors own 21.68% of the company’s stock.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.